OC
VBIV

Oppenheimer & Co’s VBI Vaccines, Inc. New Common Stock (Canada) VBIV Stock Holding History

Oppenheimer & Co’s Portfolio VBIV Stock Details VBIV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-1,450
Closed -$13.2K – 1496
2023
Q1 		$13.2K Sell
1,450
-587
-29% -$8.32K ﹤0.01% 1372
2022
Q4 		$23.9K Sell
2,037
-1,173
-37% -$20.7K ﹤0.01% 1330
2022
Q3 		$68K Sell
3,210
-50
-2% -$1.35K ﹤0.01% 1317
2022
Q2 		$80K Sell
3,260
-87
-3% -$2.96K ﹤0.01% 1349
2022
Q1 		$166K Buy
3,347
+930
+38% +$46K ﹤0.01% 1381
2021
Q4 		$170K Buy
2,417
+53
+2% +$4.47K ﹤0.01% 1411
2021
Q3 		$220K Sell
2,364
-134
-5% -$12.7K ﹤0.01% 1360
2021
Q2 		$251K Sell
2,498
-348
-12% -$33.9K ﹤0.01% 1334
2021
Q1 		$265K Buy
2,846
+212
+8% +$21.5K 0.01% 1237
2020
Q4 		$217K Buy
2,634
+34
+1% +$2.9K ﹤0.01% 1216
2020
Q3 		$223K Buy
2,600
+1,307
+101% +$152K 0.01% 1116
2020
Q2 		$120K Buy
1,293
+420
+48% +$23.1K ﹤0.01% 1195
2020
Q1 		$25K Buy
873
+343
+65% +$13.3K ﹤0.01% 1173
2019
Q4 		$22K Buy
+530
New +$11.6K ﹤0.01% 1266

Other funds holding VBIV

PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $44.6B AUM 28.94% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GAI
General American Investors New York $1.69B AUM 40.94% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Oppenheimer & Co's VBIV Position: Q2 2023 in Review

Oppenheimer & Co sold out of VBI Vaccines, Inc. New Common Stock (Canada) (VBIV) in Q2 2023, closing a stake of 1,450 shares — an estimated $13.2K sold.

Oppenheimer & Co first reported a position in VBIV in Q4 2019 and held it in 14 quarters. The position peaked at $265K in Q1 2021. 46 funds tracked by Wall St. Rank hold VBIV as of Q2 2023.

  • Oppenheimer & Co reported no remaining VBI Vaccines, Inc. New Common Stock (Canada) position as of Q2 2023 after selling out during the quarter.
  • Oppenheimer & Co sold 1,450 VBI Vaccines, Inc. New Common Stock (Canada) shares in Q2 2023, an estimated $13.2K.
  • Oppenheimer & Co first reported a position in VBI Vaccines, Inc. New Common Stock (Canada) in Q4 2019 and held it in 14 quarters.
  • Oppenheimer & Co's VBI Vaccines, Inc. New Common Stock (Canada) position peaked at $265K in Q1 2021.
  • 46 funds tracked by Wall St. Rank held VBI Vaccines, Inc. New Common Stock (Canada) as of Q2 2023.

Based on Oppenheimer & Co's 13F filing for Q2 2023, filed 3 Aug 2023.